Reborn Technology Scholar

Qin Yuanqing's work is still mainly based on scientific research. Xu Jiayi is his assistant in school affairs. He mainly focuses on the general direction. The usual internal coordination of the Twenty-Two Schools Alliance is also left to Xu Jiayi.

As the laboratories of other schools continued to be completed, the instruments and equipment donated by Qin Yuanqing to the Twenty-Two School Alliance were gradually shipped out of the warehouse and shipped to those schools. Researchers and professors from various schools who originally went to Shuimu University for training also gradually

They continued to leave Shuimu and returned to their respective schools, gearing up for a big fight.

Although Qin Yuanqing has repeatedly said in public that he does not want to be the leader of a college alliance, nor does Shuimu want to be the leader of the Twenty-Two Schools Alliance.

However, Qin Yuanqing is the largest financial backer of the Twenty-Two Schools, and Shuimu University is also the number one university in Shuimu. According to the latest rankings in the world, it has squeezed into the top ten universities, ranking tenth in the world. Shuimu University will continue to release joint scientific research.

The project is actually the sponsor of the Twenty-Two Schools Alliance.

In this era where a mother is a mother if she has breasts, Qin Yuanqing and Shuimu have become the de facto leaders of the Twenty-Two Schools Alliance and have great influence on the other Twenty-One Schools.

Qin Yuanqing went to the laboratory again. Although Qin Yuanqing became the head of Shuimu, the Automobile Research Institute, the Aerospace Engine Research Institute, and the laboratory still maintained their original operating modes, and nothing changed. It’s just that now the director of the Life Laboratory is

Yan Ning, the chemistry laboratory is run by Wu Shihao, and with two Nobel Prize winners in charge, the laboratory is developing very smoothly.

Although there are no more earth-shattering achievements, various achievements are constantly being produced, the number of patents applied for is also constantly rising, and the value of the laboratory is constantly rising.

"Principal, regarding the current mechanism of myocarditis, from the feedback from 16 hospitals, there is no deviation from the mechanism. The specific drug has entered the end of the first phase of clinical trials. So far, the results from various volunteers are relatively good.

.Tolerance tests and pharmacokinetic tests have entered the final batch of trials. It is planned to start phase II clinical trials next year. We are currently communicating with superior departments to see if we can speed up the progress of clinical trials so that specific drugs can be put on the market as soon as possible.

." Yan Ning reported on the research on myocarditis. Relying on the myocarditis mechanism model developed by Qin Yuanqing and the unique factors of myocarditis, the laboratory became a leader in the field of heart disease in the world.

Qin Yuanqing nodded slightly.

The purpose of phase I clinical trials is mainly to study the human body's response and tolerance to new drugs, explore safe and effective dosages, propose reasonable dosing regimens and precautions, provide a basis for the dosing regimen of phase II clinical trials, and evaluate the drugs.

Study pharmacokinetics such as absorption, distribution, metabolism, and excretion in the body.

It can be said that phase I clinical trials are very important.

However, whether overseas or domestic, phase I clinical trials are often ignored and the focus is on phase II clinical trials.

Of course, this kind of thing cannot be brought to the table. It is a behind-the-scenes operation. It is rare for a laboratory to jointly conduct research with multiple hospitals and conduct sample tests on a large number of volunteers for a sufficient duration.

If you want to shorten the time of clinical trials and advance the progress of clinical trials openly, there is still a way to go in China, and that is to obtain the consent of superiors. It only takes a meeting or an announcement to solve the problem.

It's just that domestic officials who can reach high positions are undoubtedly smart people. How can they not know the risks involved? To put it bluntly, no superior leader is willing to take such risks and hand over his handle obediently.

In the hands of the enemy, the enemy can use it to remove himself from power at any time.

However, the laboratory is not comparable to other institutions. This achievement directly gave birth to three Nobel Prizes in Physiology or Medicine, and there were no flaws in the first-phase clinical trial for so long. The possibility of entering the second-phase clinical trial is still

very big.

"Principal, during this period, pharmaceutical companies have been coming to us, seeking cooperation. Among them are overseas pharmaceutical giants, as well as domestic pharmaceutical giants. What do you mean?" Yan Ning hesitated for a moment, but still asked.

Since becoming the director of the life laboratory, Yan Ning has discovered that in addition to internal matters that need to be dealt with, external matters have come one after another. For example, those pharmaceutical giants also have great powers and have connected with her in various ways, making her hard to guard against.

, but some she can refuse, and some she cannot.

Although she is the director of the Life Laboratory, she is not qualified to decide such a matter. After all, Qin Yuanqing holds 90% of the laboratory's shares and is the real owner of the laboratory. She is just a researcher and a manager.

Qin Yuanqing looked thoughtful.

So far, 198 of China's top 500 companies have a market value of more than 100 billion yuan, among which 4 pharmaceutical companies have entered the top 500 companies in China, and 6 have a market value of more than 100 billion yuan. Hengrui Medicine has firmly ranked among the listed pharmaceutical companies with 246.5 billion yuan.

The leader in market value is Kangmei Pharmaceutical with 111.8 billion yuan, Fosun Pharmaceutical with 108.2 billion yuan, CSPC Pharmaceutical Group with 104.6 billion yuan, Huaxia Biopharmaceutical with 104.3 billion yuan, and Yunnan Baiyao with 103.1 billion yuan, all of which have just

Over 100 billion.

From China's top 500 companies, it can also be seen that China's industrial structure, high-end manufacturing, and Internet companies are undoubtedly at the forefront and have the highest market value.

But there is no doubt that the potential of medicine is also very great. After all, as people's income increases, the requirements for medical standards are also increasing day by day. The demand for medicine will naturally increase greatly, which means that the market is constantly expanding.

"I will handle this matter!" Qin Yuanqing pondered for a moment and said.

After understanding the situation in the laboratory, Qin Yuanqing left. After returning to the office, Qin Yuanqing asked Principal Huang, the vice president in charge of school enterprises, to come to his office.

Shuimu is also a school enterprise. It is the most important school-enterprise group in China. The 'Shuimu Department' is very representative in terms of asset and liability structure, corporate governance structure, business operation model, etc. Its reform direction and effectiveness will directly determine the direction and effectiveness of Huaxia School.

The final result of enterprise reform.

As early as 2015, superiors' document on deepening the reform of the science and technology system and mechanism proposed that the separation of high-tech enterprises and their affiliated enterprises should be gradually realized. In May 2018, a document "Guiding Opinions on the Reform of the Enterprise System Affiliated to Higher Education Institutions" was issued, requiring the promotion of

The enterprises affiliated to universities have been cleaned up and standardized, and the system has been improved to improve efficiency, prompting universities to focus on their main business of teaching and scientific research.

The scale and social impact of Shuimu University's school-run enterprises are among the first in the country. In this school-enterprise reform, Shuimu University is both a pioneer and the one that encounters the greatest difficulties. There is no way, as the number one university in China, Shuimu University must

Take the lead in implementing policy documents.

But at the same time, it is not easy to reform these high-quality assets. After all, there are a large number of excellent teams that have led the development of the school and enterprise for many years. Naturally, they are not very willing, which has stimulated fierce competition among all parties.

.

"Principal Huang, how is the current school-enterprise reform going?" Qin Yuanqing asked.

"Oh, Principal, this matter is really difficult. I'm very busy and exhausted. The difficulties are extremely great." Vice Principal Huang sighed and complained bitterly.

In 2003, Shuimu University integrated its industries and established a wholly-owned subsidiary, Shuimu Holdings. Shuimu University uses Shuimu Holdings as a platform to manage large-scale assets, covering technology industries, innovative services, technology finance, creative industries, online education, etc.

The industrial group controls 8 A-share companies including Tongfang, Chengzhi, Unisoc, Unisoc, Unisoc, TusGuhan, TusEnvironment, and Chenan Technology, with a total market value of more than 500 billion yuan. According to this year

According to the ranking, this year Shuimu Holdings ranked 87th among the top 500 domestic enterprises.

It can be said that there are three major departments under Shuimu Holdings, namely the control department, the purple light department, and the enlightenment department.

Among them, the controlling capital refers to the listed companies directly controlled by Shuimu Holdings or its wholly-owned subsidiaries, including Tongfang Co., Ltd., Chengzhi Co., Ltd. and Chenan Technology. The Ziguang Department uses Ziguang Group as the platform to control Ziguang Co., Ltd., Ziguang Guowei and Ziguang Guowei.

Optics University, holds shares in many listed companies such as Wenyi Technology; TusHoldings, through TusHoldings, controls TusGuhan and TusEnvironment. In addition, Unisplendour and TusHoldings hold shares in several A-share companies respectively, and Tongfang is the No. 1 shareholder of Tellhow Technology

Major shareholder.

Chengzhi Shares is a high-tech listed company controlled by Shuimu University that engages in the production and sales of biological products and pharmaceuticals. Currently, Shuimu Holdings directly holds 11.76% of Chengzhi Shares, and holds 33.44% through its wholly-owned subsidiary Chengzhi Kerong.

Chen'an Technology, another listed company under the Department of Shuimu Holdings, mainly relies on the technical advantages of the Public Safety Research Institute of Shuimu University to engage in the industrialization of public safety and emergency technologies. Shuimu Holdings directly holds 8.16% of the shares of Chen'an Technology, and through the full

Its subsidiary Shuimu Kongchuang holds 18.68% of the shares.

As for Tongfang Shares, it has a special status in the Shuimu Holdings family. Because of its scale and popularity, it has greater advantages than the other two listed companies. Tongfang Shares is the only A-share listed company directly controlled by Shuimu Holdings.

Relying on the scientific research strength and talent platform of Shuimu University, Shuimu Holdings takes the road of integrating industry, academia and research, positioning itself as a diversified and comprehensive science and technology industrial incubator, and is committed to the transformation and industrialization of China's high-tech achievements. As of now, Shuimu Holdings directly holds shares in Tongfang

25.75%, with Ziguang Group holding 2.35%.

Among the school-run enterprises of Shuimu University, Ziguang Department is the largest and most complex. Ziguang Group is a leading digital infrastructure and service company, and focuses on developing the electronic components and equipment manufacturing industry. As of the end of 2018, Ziguang Group has 4

It has more than 10,000 employees and total assets of approximately 270 billion yuan. Ziguang Group is the third largest mobile phone chip design company in the world, accounting for more than 20% of the global SIM card chip market share. Shuimu Holdings holds 51% of the equity of Ziguang Group, and in addition

49% belongs to Jiankun Investment. The largest shareholder of Jiankun Investment is Zhao Weiguo, holding 70% of the shares, and the other two shareholders are Li Yi and Li Luyuan, each holding 15%.

The platform of TusHoldings is TusHoldings. The latter's controlling subsidiary TusTech Services is the controlling shareholder of TusGuhan and TusEnvironment, with direct shareholding ratios of 29.44% and 16.56% respectively. TusTech Services also operates through two wholly-owned subsidiaries.

The company holds 7.48% of the shares of Tus-Environment. Tus-Holdings is a science and technology investment holding group established by Shuimu University focusing on the field of science and technology services. It is the development, construction and operation management unit of Shuimu Science and Technology Park. Tus-Holdings' official website states that the company's total assets under management exceed

200 billion yuan.

In addition to Shuimu Holdings, there is also the 'College Student Entrepreneurship Foundation' established by Shuimu University in the past ten years. The purpose of this foundation is to help Shuimu college students start their own businesses by providing entrepreneurial funds to obtain this share. This part cannot be underestimated. So far, the shareholders

The company, calculated based on the market value of shares, has also expanded rapidly to 180 billion yuan, and because the companies it participates in are all in the stage of rapid expansion, the value of this part is still growing.

Qin Yuanqing also has some headaches. To be honest, many people are very resistant to school-enterprise reform, because Shuimu's school-run enterprises are all high-quality enterprises. With Shuimu's backing, these enterprises can get technical support from Shuimu. In addition,

Shuimu has sufficient funds in recent years and does not need to suck blood from these companies, which has led to the continuous development and growth of these companies.

However, a document from superiors made Shuimu University have to bite the bullet and implement it. However, not long after, Shuimu University's restructuring encountered great difficulties and it was difficult to continue to implement it.

"Alas, I was originally thinking of supporting Chengzhi Shares and licensing some patents from the Life Laboratory to Chengzhi Shares. It seems that my thinking was too simple!" Qin Yuanqing sighed and said.

Principal Huang was shocked and said with a wry smile: "Principal, don't do this. Now we are one of the top two, and dealing with school-run enterprises is really troublesome. If you continue to support Chengzhi Shares, although you can

Rapidly growing Chengzhi Shares will make our troubles even greater. Isn’t this a blatant rebellion against our superiors?”

Qin Yuanqing rubbed his temples. To be honest, Qin Yuanqing didn't think highly of domestic pharmaceutical companies, whether they were state-owned or private companies. It is true that the investment in scientific research by these pharmaceutical giants was appalling, even if he would

After licensing patents to them, Qin Yuanqing suspected that these pharmaceutical giants would not take advantage of the opportunity to strengthen themselves and improve their scientific research capabilities to enhance their strength. Instead, they would become fat and full of oil.

This goes against Qin Yuanqing's original intention. He hoped that China's pharmaceutical companies could focus on the whole world and improve their strength to compete with overseas pharmaceutical giants, instead of letting China become a place for overseas pharmaceutical giants to arbitrarily extract excess profits.

Since leaving it to a school-run enterprise was not feasible, and he did not want to cooperate with state-owned pharmaceutical giants or private pharmaceutical giants, Qin Yuanqing couldn't help but think about setting up a pharmaceutical company by himself, and then using the patents of the laboratory to develop and grow step by step, becoming

The new pharmaceutical giant.

Pfizer, for example, became the world's pharmaceutical giant, not because the laboratory accidentally invented the little blue pill. Since then, it has been in an invincible position and conquered the world with the little blue pill.